TippingPoint Biosciences
Develops novel drug discovery platform to target epigenetic targets in pediatric brain cancer
$4.5MSeed
Role not disclosedAC
American Cancer Society BrightEdge
acsbrightedge.org ↗Activity from announced rounds
Activity in this selectionAI
American Cancer Society BrightEdge invests in cancer-focused innovation and uses financial returns to support the society’s wider mission.
Investment across the cancer-care continuum
BrightEdge is the innovation and impact-investment arm of the American Cancer Society. It brings the organisation’s cancer research and patient-support experience to businesses developing scalable responses to unmet needs, combining financial investment with strategic support.
The RoundOS financing history includes CellCentric, TippingPoint Biosciences and Cloverleaf Bio. Cloverleaf’s issuer announcement identifies BrightEdge in its RNA-therapeutics seed syndicate, while CellCentric describes BrightEdge’s backing of its cancer-drug development. These are selected company financings captured here.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $4.5M 1 disclosed · full round size, not this investor’s share